# NCT01668784 (NCT01668784)

> Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01668784
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
- Interventions: Nivolumab; Everolimus
- Enrollment: 821
- Primary outcome: Overall Survival (OS) at Primary Endpoint

## Commentary we found

- YouTube: 12
- Podcasts: 11
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct01668784

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01668784", "email": "<work email>"}; the inbox owner confirms by the emailed link.